NCT02838264 - A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

May 3, 2017

Conditions

Healthy

Interventions

DRUG

PF-06463922

Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2

DRUG

PF-06463922

Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2

DRUG

PF-06463922

Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2

DRUG

PF-06463922

Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2

DRUG

Itraconazole

200 mg oral dose of itraconazole on Days 1 to 11 during Period 2

Trial Locations (1)

Pfizer Clinical Research Unit, Brussels